These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies. Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786 [TBL] [Abstract][Full Text] [Related]
4. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272 [TBL] [Abstract][Full Text] [Related]
5. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464 [TBL] [Abstract][Full Text] [Related]
6. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077 [TBL] [Abstract][Full Text] [Related]
7. Silent and non-silent thromboembolic events after ventricular tachycardia ablation: Modifiable risk with postprocedure anticoagulation? Siontis KC; Killu AM J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1197-1199. PubMed ID: 31257655 [TBL] [Abstract][Full Text] [Related]
8. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158 [TBL] [Abstract][Full Text] [Related]
9. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation. Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038 [TBL] [Abstract][Full Text] [Related]
10. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease. Kampouraki E; Kamali F Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Naccarelli GV; Cappato R; Hohnloser SH; Marchlinski FE; Wilber DJ; Xiang J; Ma C; Hess S; Davies DW; Fields LE; Natale A; J Interv Card Electrophysiol; 2014 Nov; 41(2):107-16. PubMed ID: 25005452 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants as thromboembolic prophylaxis after catheter ablation of ventricular tachycardia: Not only safe and effective. Ejima K J Cardiovasc Electrophysiol; 2023 Apr; 34(4):973-975. PubMed ID: 36738142 [No Abstract] [Full Text] [Related]
13. Uninterrupted Direct Oral Anticoagulant and Warfarin Administration in Elderly Patients Undergoing Catheter Ablation for Atrial Fibrillation: A Comparison With Younger Patients. Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T JACC Clin Electrophysiol; 2018 May; 4(5):592-600. PubMed ID: 29798785 [TBL] [Abstract][Full Text] [Related]
14. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. Calkins H; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Serota H; Nordaby M; Guiver K; Biss B; Brouwer MA; Grimaldi M; N Engl J Med; 2017 Apr; 376(17):1627-1636. PubMed ID: 28317415 [TBL] [Abstract][Full Text] [Related]
15. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378 [TBL] [Abstract][Full Text] [Related]
16. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610 [TBL] [Abstract][Full Text] [Related]
17. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials. Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964 [TBL] [Abstract][Full Text] [Related]
19. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. Trujillo TC; Dobesh PP; Crossley GH; Finks SW Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542 [TBL] [Abstract][Full Text] [Related]
20. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]